Source: https://patents.google.com/patent/US7923463B2/en
Timestamp: 2019-04-19 15:42:31+00:00

Document:
2010-02-23 First worldwide family litigation filed litigation https://patents.darts-ip.com/?family=38088358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7923463(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
This application is a continuation of U.S. application Ser. No. 12/334,255, filed Dec. 12, 2008, now U.S. Pat. No. 7,655,672, which application is a continuation of U.S. application Ser. No. 11/276,324, filed Feb. 24, 2006, which application is a continuation of U.S. application Ser. No. 11/303,659, filed Dec. 16, 2005, now abandoned which application claims the benefit of U.S. Provisional Application Ser. No. 60/636,916 filed Dec. 17, 2004, the teachings of all being incorporated herein by reference in their entirety. This application also is a divisional of co-pending U.S. application Ser. No. 11/276,324, filed Feb. 24, 2006, which application is a continuation of U.S. application Ser. No. 11/303,659, filed Dec. 16, 2005, which application claims the benefit of U.S. Provisional Application Ser. No. 60/636,916 filed Dec. 17, 2004, the teachings of all being incorporated herein by reference in their entirety.
maintaining a greater amount of the therapeutically effective amount of imiquimod in the pharmaceutical cream during said storing of the pharmaceutical cream, as compared to a reduced amount of imiquimod maintained in an identical pharmaceutical imiquimod cream but formulated with a compendial grade oleic acid component when the pharmaceutical cream and the identical pharmaceutical imiquimod cream are each stored under identical storage conditions for an equal period of time after formulation for up to about six months.
2. The method of claim 1, wherein said pharmaceutical cream has been stored for up to about six months prior to said application of the pharmaceutical cream.
3. The method of claim 1, wherein said pharmaceutical cream has been stored for up to about four months prior to said application of the pharmaceutical cream.
4. The method of claim 1, wherein said pharmaceutical cream has been stored for up to about two months prior to said application of the pharmaceutical cream.
5. The method of claim 1, wherein said pharmaceutical cream further comprises an antioxidant selected from the group consisting of butylated hydroxyl toluene (BHT) and butylated hydroxyanisole (BHA).
6. The method of claim 1, wherein the imiquimod is present in an amount of not more than 10% by weight based on the total weight of said pharmaceutical cream and wherein the oleic acid component is present in an amount of no more than about 40% by weight based on the total weight of said pharmaceutical cream.
7. The method of claim 1, wherein the imiquimod is present in an amount of about 5% by weight based on the total weight of said pharmaceutical cream and wherein the oleic acid component is present in an amount of about 28% by weight based on the total weight of said pharmaceutical cream.
8. The method of claim 1, wherein the imiquimod is present in an amount of about 5% by weight based on the total weight of said pharmaceutical cream and wherein the oleic acid component is present in an amount of about 25% by weight based on the total weight of said pharmaceutical cream.
9. The method of claim 1, wherein said oleic acid component is Super Refined oleic acid NF.
"Chronological History of Lipid Science, History of Lipids (1669-2008)", http://www.cyberlipid.org/history1.htm pp. 1-55.
"What is Oleic Acid?", wiseGEEK, http://www.wisegeek.com/what-is-oleic-acid.htm, 3 pages, (Apr. 9, 2008).
Amendment and Response to U.S. Appl. No. 07/845,323 (U.S. Patent No. 5,238,944) with Affidavit of Dr. Berge.
Bouman et al., "Preparation and purification of lovastatin derivatives used as hydroxymethyl glutaryl coenzyme A reductase inhibitors-comprises adjusting pH, removing cells used to prepare them, heating and contacting with resin", The Delphion Inegrated View: INPADOC Record, Acessio No. 1998-570544/200225, (Nov. 11, 1998).
Bouman et al., "Preparation and purification of lovastatin derivatives used as hydroxymethyl glutaryl coenzyme A reductase inhibitors—comprises adjusting pH, removing cells used to prepare them, heating and contacting with resin", The Delphion Inegrated View: INPADOC Record, Acessio No. 1998-570544/200225, (Nov. 11, 1998).
Chemical Engineering of Japan, 67(4), pp. 233, 235 (Apr. 5, 2003).
Chollet, J.L. et al., "Crystal Formation by Drug-Excipient Interaction in a Topical I miquimod Formulation," 1998 AAPS Annual Meeting; Oct. 1998.
Croda-Super Refined Oleic Acid NF, (Nov. 5, 2002).
Croda—Super Refined Oleic Acid NF, (Nov. 5, 2002).
Feb. 23, 2010 Nordsiek Declaration with Exhibits A & B; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937(WJM-MF).
Feb. 23, 2010 Nordsiek Exhibit D; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937(WJM-MF).
Feb. 23, 2010 Novak Exhibit 6; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937(WJM-MF).
Feb. 28, 2010 TRO Brief; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv00937(WJM-MF).
Fragrance Journal, 5(6), Issue No. 27, pp. 28-35 (Nov. 25, 1977) -.
Goliath et al., "Super Refined Oleic Acid Available from Croda", Household & Personal Products Industry, http://goliath.ecnext.com, pp. 1-2, (Feb. 1, 2003).
Google News Archive Search, "Timeline for of Refining Oleic Acid", and "Production and Market of Fatty Acid and Dimer Acid in China", http://news.google.com/archivesearch:http://www.marketresearch.com/product/display, 5 pages, (Apr. 7, 2008).
Joint Claim Construction and Prehearing Statement ; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937, Nov. 29, 2010.
Mar. 8, 2010 Opinion on Temporary Restraining Order; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937 (WJM-MF).
Olive Oil Definitions-The Olive Oil Source, http://www.oliveoilsource.com/definitions.htm, 8 pages, (Apr. 15, 2008).
Olive Oil Definitions—The Olive Oil Source, http://www.oliveoilsource.com/definitions.htm, 8 pages, (Apr. 15, 2008).
Pacer Docket Sheets as of Dec. 28, 2010; Graceway Pharmaceuticals, LLC and 3M Innovative Properties Company v. Perrigo Company et al., U.S. District Court, District of New Jersey, Case No. 2:10-cv-00937 (WJM-MF).
The Delphion Integrated View: INPADOC Record, Ciba Geigy AG, "Imidazo (4,5-c) quinoline preparation-consists of reduction of a lower alkylene di:oxy cpd. through reaction with ammonia, etc.) or cpd. of formula (II) is reacted with e.g. ammonia", Accession No. 1984-168891/198427, (May 29, 1984).
The Delphion Integrated View: INPADOC Record, Ciba Geigy AG, "Imidazo (4,5-c) quinoline preparation—consists of reduction of a lower alkylene di:oxy cpd. through reaction with ammonia, etc.) or cpd. of formula (II) is reacted with e.g. ammonia", Accession No. 1984-168891/198427, (May 29, 1984).
U.R. Hengge et al., Errata,The LANCET Infectious Diseases, vol. 2, p. 259 (2002).
USP Certificate-Oleic Acid LOT F0E001, Cat. No. 1478130, (Jan. 12, 2004).
USP Certificate—Oleic Acid LOT F0E001, Cat. No. 1478130, (Jan. 12, 2004).
USP Material Safety Data Sheet, "Oleic Acid", Catalog Number: 1478130, U.S. Pharmacopeia, pp. 1-6 (2004).

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.